Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LMP01
- Development stage
- Preclinical
- Lead developer
- Curatio
- Modality
- Small Molecules
01
Overview
**LMP01** is Curatio's investigational, uniquely coded combination therapy for glioblastoma multiforme and other brain cancers. It comprises two undisclosed small-molecule active substances intended to attack two brain-cancer targets simultaneously through an undisclosed novel administration route; Curatio states that one component is FDA-approved for another indication and the other is generally recognized as safe. The company has not publicly identified the components, molecular targets, dosage form, route, or clinical phase. ([curatiotx.com](https://www.curatiotx.com/lmp01_curatio_therapeutics.html))
- Other names
- LMP 01LMP01LMP-01
Beyond the preview
Go deeper on LMP01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LMP01.